君实生物(01877.HK):特瑞普利单抗注射液新适应症上市申请获受理

阿斯达克财经
Oct 29

君实生物(01877.HK) 公布,公司收到国家药监督局核准签发的《受理通知书》,公司产品特瑞普利单抗注射液(皮下注射)(代号:JS001sc)联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌治疗的新适应症上市申请获得受理。特瑞普利单抗注射液(皮下注射)针对特瑞普利单抗注射液(商品名:拓益(R),产品代号:JS001)已获批的全部13项适应症的上市申请均已获得受理。另外,特瑞普利单抗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10